Reset filter
Palavras-chave
Servicios de Laboratorio Clínico ×
Mostrar mais Palavras-chave
Índice
  1. 1. Estudo clínico
  2. 2. Documentação de rotina
  3. 3. Estudos de registo/coortes
  4. 4. Garantia da qualidade
  5. 5. Padrão de dados
  6. 6. Questionário do paciente
  7. 7. Especialidade médica
Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

64 Resultados da pesquisa.
Relevância Avaliação Novos primeiro Antigos primeiro

Effect of Lamictal on Resting Motor Threshold Study-ID 107434 - Blood Sample for Pharmacogenetic Research

- 09/01/2019 - 1 Formulário, 5 Grupos de itens, 16 Elementos de dados, 1 Idioma
Grupos de itens: Administrative Data, Pharmagogenetic Research, Sample Collection, Withdrawal of Consent, Sample Destruction
Study ID: 107434 Clinical Study ID: NAP107434 Study Title: A randomised, double-blind, double-dummy, placebo controlled, three-way cross-over study to investigate the effect of single oral doses of 100 mg GW273225 (4030W92) and 325 mg LAMICTAL on resting motor threshold in healthy subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Study Link: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GW273225 Trade Name: lamictal Study Indication: Bipolar Disorder This form contains information concerning the blood sample taken for pharmacogenetic research, it should be filled out at a time point post dose. It should be filled out at each treatment period. Screening Visit: 28 days prior to first dosing. Treatment Period: The day before dosing, until 48h after dosing. Follow-Up: 14-21 days after last dose

Effect of Lamictal on Resting Motor Threshold Study-ID 107434 - Clinical Laboratory Safety Tests

- 25/12/2018 - 1 Formulário, 4 Grupos de itens, 17 Elementos de dados, 1 Idioma
Grupos de itens: Administrative Data, Blood Tests, Urine Tests, HIV I and II
Study ID: 107434 Clinical Study ID: NAP107434 Study Title: A randomised, double-blind, double-dummy, placebo controlled, three-way cross-over study to investigate the effect of single oral doses of 100 mg GW273225 (4030W92) and 325 mg LAMICTAL on resting motor threshold in healthy subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Study Link: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GW273225 Trade Name: lamictal Study Indication: Bipolar Disorder This form contains information concerning clinical laboratory safety tests of the subject. It should be filled out at the screening visit. Screening Visit: 28 days prior to first dosing. Treatment Period: The day before dosing, until 48h after dosing. Follow-Up: 14-21 days after last dose

Sumatriptan pharmacokinetics for TREXIMA/IMITREX NCT00875784 - Electronically Transferred Lab Data

- 21/11/2018 - 1 Formulário, 2 Grupos de itens, 9 Elementos de dados, 1 Idioma
Grupos de itens: Administrative Data, Lab
This form contains a form to document the results of the electronically transferred lab data. To be assessed at screening, follow-up and where required early withdrawal visit. Study ID: 103629 Clinical Study ID: TRX103629 Study Title: An open-label, randomized, 3-period crossover study to evaluate sumatriptan and naproxen pharmacokinetics for a combination tablet product containing sumatriptan/naproxen sodium followed by IMITREX™ (sumatriptan succinate) Injection 4mg administered using the IMITREX STATdose System and a sumatriptan/naproxen sodium tablet followed by IMITREX (sumatriptan succinate) Injection 6mg administered using the STATdose system compared with an IMITREX tablet 100mg followed by an IMITREX tablet 100mg Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00875784 Clinicaltrials.gov link: https://clinicaltrials.gov/ct2/show/NCT00875784 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 1 Study Recruitment Status: Completed Generic Name: sumatriptan Trade Name: Imitrex ,Imiject ,Imigran; Imitrex,Imiject,Imigran Study Indication: Migraine Disorders

Efficacy, Safety and Immunogenicity of Oral HRV Vaccine NCT00241644 - Laboratory Tests Visit 4

- 01/11/2018 - 1 Formulário, 2 Grupos de itens, 5 Elementos de dados, 1 Idioma
Grupos de itens: Administrative Data, Laboratory Tests
Study ID: 102248 Clinical Study ID: 102248 Study Title: Multi-Center Study to Assess the Efficacy, Safety and Immunogenicity of 2 or 3 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine Given Concomitantly With Routine EPI Vaccinations in Healthy Infants Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00241644 Study Link: https://clinicaltrials.gov/ct2/show/NCT00241644 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Rotavirus Vaccine Trade Name: Rotarix Study Indication: Infections, Rotavirus The visits are defined as follows: Visit 1: (Study/Participation) Day 0, Age: 5-10 weeks, Dose 1 Visit 2: (Study/Participation) Month 1, 30-48 days after Visit 1, Dose 2 Visit 3: (Study/Participation) Month 2, 30-48 days after Visit 2, Dose 3 Visit 4: (Study/Participation) Month 3, 30-48 days after Visit 3, Visit 5: (Study/Participation) 1 year of age, 343-391 days of age For amendment 5: Visit 5: (Study/Participation) 21-48 days after Visit 4 Visit 6: (Study/Participation) 1 year of age, 343-391 days of age This form asks for taking a 3ml blood sample at third visit and asks for results for HIV assay. It should be checked at Visit 4.

Efficacy, Safety and Immunogenicity of Oral HRV Vaccine NCT00241644 - Laboratory Tests Visit 1

- 01/11/2018 - 1 Formulário, 3 Grupos de itens, 6 Elementos de dados, 1 Idioma
Grupos de itens: Administrative Data, Laboratory Tests, Medical History for HIV
Study ID: 102248 Clinical Study ID: 102248 Study Title: Multi-Center Study to Assess the Efficacy, Safety and Immunogenicity of 2 or 3 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine Given Concomitantly With Routine EPI Vaccinations in Healthy Infants Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00241644 Study Link: https://clinicaltrials.gov/ct2/show/NCT00241644 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Rotavirus Vaccine Trade Name: Rotarix Study Indication: Infections, Rotavirus The visits are defined as follows: Visit 1: (Study/Participation) Day 0, Age: 5-10 weeks, Dose 1 Visit 2: (Study/Participation) Month 1, 30-48 days after Visit 1, Dose 2 Visit 3: (Study/Participation) Month 2, 30-48 days after Visit 2, Dose 3 Visit 4: (Study/Participation) Month 3, 30-48 days after Visit 3, Visit 5: (Study/Participation) 1 year of age, 343-391 days of age For amendment 5: Visit 5: (Study/Participation) 21-48 days after Visit 4 Visit 6: (Study/Participation) 1 year of age, 343-391 days of age This form asks, if a blood sample has been taken from the patient and should be checked at visit 1.

openEHR-EHR-CLUSTER.laboratory_test_panel.v0

- 10/04/2018 - 1 Formulário, 1 Grupo de itens, 9 Elementos de dados, 2 Idiomas
Grupo de itens: openEHR-EHR-CLUSTER.laboratory_test_panel.v0.xml
http://openehr.org/ckm/ To record laboratory test results as a single value or in a panel/battery format common to clinical pathology testing such as biochemistry, haematology and immunology. Normally used in conjunction with a parent Laboratory test result (Observation) archetype. The name attribute of the Laboratory test panel/Result value element is normally replaced in a template or at run-time to carry the name of the specific analyte e.g. 'Haemoglobin', often coded with a reference terminology such as LOINC, SNOMED CT or NPU. Where other more complex result patterns are required it may be helpful to specialise this archetype or substitute another.

Meningococcal Infections Vaccination in children NCT00196976 - Workbook 2 Visit 3 Part 2

- 08/11/2017 - 1 Formulário, 8 Grupos de itens, 22 Elementos de dados, 1 Idioma
Grupos de itens: Administrative Documentation, GENERAL MEDICAL HISTORY | PHYSICAL EXAMINATION, GENERAL MEDICAL HISTORY | PHYSICAL EXAMINATION, Vaccine History, Vaccine History, Medication history, Medication History, LABORATORY TESTS
Study ID: 103534 Clinical Study ID: 103534 Study Title: Evaluate the immunogenicity, reactogenicity, safety of 4 different formulations of GSK Biologicals' conjugate vaccine (MenACWY) vs 1 dose of MenC-CRM197 or Mencevax™ ACWY in children aged 12-14 months & 3-5 years Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00196976 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed clinical study under GSK sponsorship. The product that is studied in this clinical study, together with the rights to the data and results generated, has been transferred by GSK to Pfizer. GSK’s Clinical Study Register is no longer maintained for this study. To request access to clinical study data from Pfizer, go here: http://www.pfizer.com/research/clinical_trials/trial_data_and_results Generic Name: Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine Trade Name: Nimenrix Study Indication: Infections, Meningococcal Booster Vaccination Only for subjects who are part of the group with the selected MenACWY-TT formulation and the control group.) “Subjects enrolled at 3 – 5 years of age”

Meningococcal Infections Vaccination in children NCT00196976 - Workbook 1 Visit 4 Part 2

- 04/11/2017 - 1 Formulário, 8 Grupos de itens, 22 Elementos de dados, 1 Idioma
Grupos de itens: Administrative Documentation, GENERAL MEDICAL HISTORY | PHYSICAL EXAMINATION, GENERAL MEDICAL HISTORY | PHYSICAL EXAMINATION, Vaccine History, Vaccine History, Medication history, Medication History, LABORATORY TESTS
Study ID: 103534 Clinical Study ID: 103534 Study Title: Evaluate the immunogenicity, reactogenicity, safety of 4 different formulations of GSK Biologicals' conjugate vaccine (MenACWY) vs 1 dose of MenC-CRM197 or Mencevax™ ACWY in children aged 12-14 months & 3-5 years Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00196976 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed clinical study under GSK sponsorship. The product that is studied in this clinical study, together with the rights to the data and results generated, has been transferred by GSK to Pfizer. GSK’s Clinical Study Register is no longer maintained for this study. To request access to clinical study data from Pfizer, go here: http://www.pfizer.com/research/clinical_trials/trial_data_and_results Generic Name: Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine Trade Name: Nimenrix Study Indication: Infections, Meningococcal

7% CO2, GW597599, paroxetine andor alprazolam in healthy volunteers 100690 - Follow-Up Unscheduled

- 23/10/2017 - 1 Formulário, 3 Grupos de itens, 7 Elementos de dados, 1 Idioma
Grupos de itens: Administrative Documentation, Clinical Chemistry and Haematology, Urinalysis
Study ID: 100690 Clinical Study ID: NKP100690 Study Title: A randomised, double blind triple dummy, placebo controlled balanced incomplete block crossover study to evaluate the change in response to a 7% CO2 challenge and pharmacokinetics of single oral doses of GW597599 and paroxetine (5 or 7.5 mg) either alone or in combination, or alprazolam (0.75 mg) in healthy volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 1 Study Recruitment Status: Completed Generic Name: paroxetine Trade Name: Tagonis,Seroxat,Paxil,Paroxat,Deroxat,Aropax Study Indication: Depressive Disorder and Anxiety Disorders CRF Seiten: 255-365

7% CO2, GW597599, paroxetine andor alprazolam in healthy volunteers 100690 - Session 3 Day 2 Unscheduled

- 23/10/2017 - 1 Formulário, 3 Grupos de itens, 7 Elementos de dados, 1 Idioma
Grupos de itens: Administrative Documentation, Clinical Chemistry and Haematology, Urinalysis
Study ID: 100690 Clinical Study ID: NKP100690 Study Title: A randomised, double blind triple dummy, placebo controlled balanced incomplete block crossover study to evaluate the change in response to a 7% CO2 challenge and pharmacokinetics of single oral doses of GW597599 and paroxetine (5 or 7.5 mg) either alone or in combination, or alprazolam (0.75 mg) in healthy volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 1 Study Recruitment Status: Completed Generic Name: paroxetine Trade Name: Tagonis,Seroxat,Paxil,Paroxat,Deroxat,Aropax Study Indication: Depressive Disorder and Anxiety Disorders CRF Seiten: 255-365

7% CO2, GW597599, paroxetine andor alprazolam in healthy volunteers 100690 - Session 3 Day 2

- 23/10/2017 - 1 Formulário, 3 Grupos de itens, 7 Elementos de dados, 1 Idioma
Grupos de itens: Administrative Documentation, Clinical Chemistry and Haematology, Urinalysis
Study ID: 100690 Clinical Study ID: NKP100690 Study Title: A randomised, double blind triple dummy, placebo controlled balanced incomplete block crossover study to evaluate the change in response to a 7% CO2 challenge and pharmacokinetics of single oral doses of GW597599 and paroxetine (5 or 7.5 mg) either alone or in combination, or alprazolam (0.75 mg) in healthy volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 1 Study Recruitment Status: Completed Generic Name: paroxetine Trade Name: Tagonis,Seroxat,Paxil,Paroxat,Deroxat,Aropax Study Indication: Depressive Disorder and Anxiety Disorders CRF Seiten: 255-365

7% CO2, GW597599, paroxetine andor alprazolam in healthy volunteers 100690 - Session 3 Day 1 Pre-Dose

- 23/10/2017 - 1 Formulário, 4 Grupos de itens, 11 Elementos de dados, 1 Idioma
Grupos de itens: Administrative Documentation, Urine Pregnancy Test, Clinical Chemistry and Haematology, Urinalysis
Study ID: 100690 Clinical Study ID: NKP100690 Study Title: A randomised, double blind triple dummy, placebo controlled balanced incomplete block crossover study to evaluate the change in response to a 7% CO2 challenge and pharmacokinetics of single oral doses of GW597599 and paroxetine (5 or 7.5 mg) either alone or in combination, or alprazolam (0.75 mg) in healthy volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 1 Study Recruitment Status: Completed Generic Name: paroxetine Trade Name: Tagonis,Seroxat,Paxil,Paroxat,Deroxat,Aropax Study Indication: Depressive Disorder and Anxiety Disorders CRF Seiten: 255-365

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial